Icon Advisers Inc. Co. bought a new stake in shares of China Biologic Products Inc. (NASDAQ:CBPO) during the third quarter, Holdings Channel reports. The fund bought 15,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,929,000.

A number of other institutional investors also recently added to or reduced their stakes in CBPO. BNP Paribas Arbitrage SA boosted its position in China Biologic Products by 3,357.5% in the third quarter. BNP Paribas Arbitrage SA now owns 1,383 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 1,343 shares during the last quarter. BlackRock Investment Management LLC bought a new position in China Biologic Products during the second quarter valued at approximately $158,000. Capstone Investment Advisors LLC bought a new position in China Biologic Products during the second quarter valued at approximately $223,000. Legal & General Group Plc boosted its position in China Biologic Products by 23.5% in the second quarter. Legal & General Group Plc now owns 2,101 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 400 shares during the last quarter. Finally, Capital Fund Management S.A. bought a new position in China Biologic Products during the second quarter valued at approximately $268,000. 70.11% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

China Biologic Products Inc. (NASDAQ:CBPO) traded up 1.15% during trading on Tuesday, hitting $120.28. 157,680 shares of the stock traded hands. The stock has a market cap of $3.26 billion, a P/E ratio of 32.98 and a beta of 1.70. China Biologic Products Inc. has a 52 week low of $100.53 and a 52 week high of $144.29. The firm’s 50-day moving average is $118.52 and its 200 day moving average is $116.86.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported $1.22 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.17. China Biologic Products had a net margin of 30.63% and a return on equity of 19.61%. The company had revenue of $86.50 million for the quarter, compared to the consensus estimate of $88.46 million. During the same quarter in the previous year, the company earned $0.99 EPS. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. Equities research analysts forecast that China Biologic Products Inc. will post $4.51 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the propert of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this article can be viewed at http://www.dailypolitical.com/2016/11/29/icon-advisers-inc-co-invests-1929000-in-china-biologic-products-inc-cbpo.html.

Several equities analysts have recently weighed in on the stock. Jefferies Group restated a “buy” rating and set a $155.00 price objective on shares of China Biologic Products in a research report on Friday, November 4th. Zacks Investment Research lowered shares of China Biologic Products from a “buy” rating to a “hold” rating in a research report on Friday, August 12th.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

5 Day Chart for NASDAQ:CBPO

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Inc. (NASDAQ:CBPO).

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.